Table 3.

Baseline characteristics of patients included in the studies comparing mitral valve-in-valve versus redo surgical mitral valve replacement in patients with degenerated mitral prostheses.

	Simard et al,12 2022		Zubarevich et al,11 2021		Khan et al,9 2021		Simonetto et al,6 2021		Osman et al,13 2020		Kamioka et al,10 2018		Murzi et al,8 2017
	TMVR	Redo-SMVR	TMVR	Redo-SMVR	TMVR	Redo-SMVR	TMVR	Redo-SMVR	TMVR	Redo-SMVR	TMVR	Redo-SMVR	TMVR	Redo-SMVR
Sample size	86	129	41	33	495	2250	49	29	384	1404	62	59	21	40
Age, y	74.9	64.5	73.6	63.7	77	68	77.6	67.7	76	68	74.9	63.7	77	67
Female, n (%)	54 (62.8)	81 (62.8)	19 (46.3)	22 (66.7)	260 (52.5)	1150 (51.1)	20 (40.8)	13 (44.8)	215 (56)	769 (54.8)	38 (61.3)	36 (61)	13 (61.9)	23 (56.1)
Diabetes mellitus	15 (17.4)	24 (18.6)	14 (34.1)	4 (12.1)	40 (8.1)	185 (8.2)	9 (18.3)	4 (14.8)	133 (34.6)	543 (38.7)	15 (24.2)	7 (11.9)	5 (23.8)	4 (9.8)
Chronic lung disease	30 (34.9)	26 (20.2)	17 (41.5)	5 (15.2)	140 (28.3)	575 (25.6)	4 (8.2)a	3 (10.7)a	n/a	n/a	21 (33.9)b	8 (13.6)b	3 (14.2)	5 (12.2)
NYHA class III or IV	85 (98.8)	89 (69)	41 (100)	24 (72.7)	n/a	n/a	42 (85.7)	16 (57.2)	n/a	n/a	Class IV: 19 (30.7)	Class IV: 19 (32.2)	18 (85.7)	29 (70.7)
STS score	n/a	n/a	11.9	10.2	n/a	n/a	8.7	3.6	n/a	n/a	12.7	8.7	n/a	n/a
Logistic EuroSCORE	n/a	n/a	42.3	32.6	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	39	23
EuroSCORE II	n/a	n/a	21.2	18.2	n/a	n/a	12.1	5.5	n/a	n/a	n/a	n/a	n/a	n/a
Ejection fraction	58.7	59.3	45.4	52.2	n/a	n/a	59.7	59.7	n/a	n/a	54.6	55.7	50	53

EuroSCORE, European System for Cardiac Operative Risk Evaluation; n/a, not available; NYHA, New York Heart Association; SMVR, surgical mitral valve replacement; STS, Society of Thoracic Surgeons; TMVR, transcatheter mitral valve replacement.

^aSevere.

^b≥Moderate.